Abstract 40P
Background
Immune checkpoint inhibitors have become standard of care for many cancer subtypes. Next generation immuno-oncology (IO) agents are in clinical testing, with thousands of combinations in preclinical evaluation. The success of current and future immunotherapies relies on tools, data and technology to rationalize their use and manage toxicity. However, few biomarkers can distinguish responders from non-responders, predict toxicity, or guide treatment choices.
Methods
MANIFEST (https://www.manifest-io.org.uk/), a UKRI/MRC funded platform, leverages scalable methodologies to provide deep profiling of patients receiving immunotherapy; delivering multimodal data integration and modelling. The platform comprises NHS trusts (hospitals), research institutes and universities, and industry partners. The aims of MANIFEST is to harmonise sampling, assays and analyses of IO biomarkers and couple them with large-scale studies in patients with cancer. The platform’s utility will be demonstrated with exemplar projects encompassing multiple tumour types (melanoma, renal cell carcinoma, bladder cancer and triple-negative breast cancer), where predicting treatment outcomes and toxicities remains an unmet need.
Results
We have access to longitudinal samples of >3,000 patients across 10 reported studies. Through partner NHS sites, we aim to prospectively collect and profile samples (blood, stool and tumour) from ∼3,000 patients over 3 years. A tiered approach will implement workflows for high-volume biomarker discovery (Tier 1). In-depth profiling (Tiers 2&3) will further characterize tumours using peripheral immune profiling including high-dimensional flow cytometry, liquid biopsy (cfDNA, immune methylation profiling), spatial tissue image-profiling and molecular profiling (WES, bulk&long-read RNAseq, TCR&BCRseq). For selected patients, we will apply Representative Sequencing (RepSeq), to overcome sampling bias in solid tumours and conduct drug-sensitivity screening through patient-derived tumour fragments.
Conclusions
Machine learning will be applied to derive uni- and multi- modal biomarkers of response and toxicity, and the master databases will be available for ongoing academic and industry research.
Legal entity responsible for the study
The Francis Crick Institute & The MANIFEST Consortium.
Funding
UKRI, Medical Research Council and Office of Life Sciences.
Disclosure
T. Lawley: Financial Interests, Institutional, Leadership Role: Microbiotica. All other authors have declared no conflicts of interest.
Resources from the same session
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract